14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ZBIO vs CHAD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ZBIO Overall Winner
6-Pillar Tally: ZBIO 4 – 0 CHAD (2 Tie)
Matrix Metrics: ZBIO 5 – 3 CHAD
As of Nov 16, 2026, Zenas BioPharma, Inc. (ZBIO) is the stronger overall head-to-head candidate over CHAD (CHAD) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ZBIO carries a Unified Composite Score of 49.4/100 (HOLD) at $27.93 (N/M Forward P/E, -2747.5% operating margin), whereas CHAD carries 53.8/100 (HOLD) at $10.00 (N/M Forward P/E, N/A operating margin).
Composite vs. Pillar Nuance: While CHAD currently prints a higher short-term Unified Composite Score (53.8/100 HOLD vs. ZBIO 49.4/100 HOLD), ZBIO captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-2747.5% vs. N/A operating margin) and revenue trajectory (-100.0% vs. N/A YoY).
Technical & Structure Timing Caution: ZBIO is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0); meanwhile CHAD trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ZBIO vs CHAD. Trailing 12-month operating profitability (ZBIO -2747.5% vs CHAD N/A) and valuation multiples (ZBIO N/M vs CHAD N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.9B market capitalization and -2747.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
CHAD Moat ProfileCyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ZBIO vs CHAD Key Questions & Quantitative Answers
As of Nov 16, 2026, Zenas BioPharma, Inc. (ZBIO) is the stronger overall head-to-head candidate over CHAD (CHAD) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ZBIO carries a Unified Composite Score of 49.4/100 (HOLD) at $27.93 (N/M Forward P/E, -2747.5% operating margin), whereas CHAD carries 53.8/100 (HOLD) at $10.00 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While CHAD currently prints a higher short-term Unified Composite Score (53.8/100 HOLD vs. ZBIO 49.4/100 HOLD), ZBIO captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-2747.5% vs. N/A operating margin) and revenue trajectory (-100.0% vs. N/A YoY). Technical & Structure Timing Caution: ZBIO is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0); meanwhile CHAD trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ZBIO leads the Growth & Scale pillar: ZBIO posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -2747.5% operating margin), compared with CHAD at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, ZBIO generates $11M in USD-normalized revenue versus N/A for CHAD. In operating R&D and SG&A reinvestment, ZBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CHAD.
ZBIO and CHAD trade at balanced relative valuation multiples. ZBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CHAD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ZBIO (-265.1% ROE) versus CHAD (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, ZBIO carries 103.9% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.16β · 59% Vol realized risk). By comparison, CHAD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.71β · 11% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.